[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR120961A2 - Método y composición para tratar hipertensión ocular y glaucoma - Google Patents

Método y composición para tratar hipertensión ocular y glaucoma

Info

Publication number
AR120961A2
AR120961A2 ARP180103181A ARP180103181A AR120961A2 AR 120961 A2 AR120961 A2 AR 120961A2 AR P180103181 A ARP180103181 A AR P180103181A AR P180103181 A ARP180103181 A AR P180103181A AR 120961 A2 AR120961 A2 AR 120961A2
Authority
AR
Argentina
Prior art keywords
glaucoma
composition
ocular hypertension
treat ocular
aqueous
Prior art date
Application number
ARP180103181A
Other languages
English (en)
Inventor
Kari Lehmussaari
Olli Oksala
Pertti Pellinen
Timo Reunamki
Original Assignee
Santen Pharmaceutical Co Ltd
Agc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR120961(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Agc Inc filed Critical Santen Pharmaceutical Co Ltd
Publication of AR120961A2 publication Critical patent/AR120961A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una composición acuosa oftálmica que contiene análogos de PGF2a para tratar la hipertensión ocular y el glaucoma, a un método para tratar la hipertensión ocular y el glaucoma administrando dicha composición a un sujeto que necesita de tal tratamiento, y a un método para aumentar la solubilidad acuosa y mejorar la estabilidad de los análogos de PGF2a en una composición acuosa.
ARP180103181A 2008-05-30 2018-11-01 Método y composición para tratar hipertensión ocular y glaucoma AR120961A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
AR120961A2 true AR120961A2 (es) 2022-04-06

Family

ID=39940592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090101912A AR071937A1 (es) 2008-05-30 2009-05-28 Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa
ARP180103181A AR120961A2 (es) 2008-05-30 2018-11-01 Método y composición para tratar hipertensión ocular y glaucoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090101912A AR071937A1 (es) 2008-05-30 2009-05-28 Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa

Country Status (27)

Country Link
US (3) US9999593B2 (es)
EP (7) EP2127638A1 (es)
JP (9) JP2011521943A (es)
KR (5) KR101988642B1 (es)
CN (1) CN102083413B (es)
AR (2) AR071937A1 (es)
AU (1) AU2009252210C1 (es)
BR (1) BRPI0913109B8 (es)
CA (2) CA2724194C (es)
CY (2) CY1115565T1 (es)
DK (4) DK2772249T3 (es)
EA (1) EA023661B1 (es)
ES (5) ES2907982T3 (es)
GE (1) GEP20156220B (es)
HR (4) HRP20220361T1 (es)
HU (3) HUE058079T2 (es)
JO (1) JO3039B1 (es)
LT (3) LT3714877T (es)
MX (1) MX2010012987A (es)
MY (1) MY159463A (es)
PL (4) PL3714877T3 (es)
PT (4) PT2772249T (es)
SG (1) SG191628A1 (es)
SI (4) SI2306977T1 (es)
TW (1) TWI432202B (es)
UA (1) UA102257C2 (es)
WO (1) WO2009145356A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
ES2708451T3 (es) * 2010-07-29 2019-04-09 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
CA2806973A1 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
ES2616089T3 (es) * 2010-09-21 2017-06-09 S & V Technologies Gmbh Composición cosmética
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
AU2013305539B2 (en) * 2012-08-24 2018-08-02 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
WO2017078953A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用
PL3423076T3 (pl) 2016-02-29 2024-08-19 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego zawierające cyklosporynę i ich zastosowania
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
EP3603642B1 (en) * 2017-03-27 2024-01-10 Alcon Inc. Pharmaceutical preparation
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
WO2018236158A1 (ko) 2017-06-22 2018-12-27 연성정밀화학(주) 녹내장 치료용 점안 조성물
TWI788484B (zh) * 2017-12-21 2023-01-01 日商參天製藥股份有限公司 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
EP3820445A1 (en) 2018-07-09 2021-05-19 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
DE3871596T3 (de) 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6241124B1 (en) 1996-12-09 2001-06-05 Bausch & Lomb Incorporated Single-use container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
DK0979652T3 (da) * 1997-10-13 2006-09-11 R Tech Ueno Ltd Helbredende præparat til intraokulær hypertension eller glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AU743607B2 (en) * 1998-07-14 2002-01-31 Alcon Laboratories, Inc. Prostaglandin product
JP2003517441A (ja) 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PT1466889E (pt) 1999-04-06 2008-07-02 Sepracor Inc Succinato de o-desmetilvenlafaxina
CA2413088C (en) 2000-06-19 2009-10-20 Kenji Morishima Preservative
CA2422031C (en) 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
JP4402591B2 (ja) 2002-07-16 2010-01-20 千寿製薬株式会社 薬液容器及びその製造方法
CA2707068A1 (en) 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
WO2007042262A2 (en) 2005-10-10 2007-04-19 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
CN101175496A (zh) 2004-12-24 2008-05-07 参天制药株式会社 含有前列腺素F2α衍生物的制品
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CN101222939B (zh) 2005-07-13 2010-11-24 参天制药株式会社 眼科用防腐组合物
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
KR101988642B1 (ko) 2019-06-12
HRP20220361T1 (hr) 2022-05-13
JP2017178957A (ja) 2017-10-05
PL3714877T3 (pl) 2022-05-16
JP7265584B2 (ja) 2023-04-26
EP4289446A3 (en) 2024-01-10
EA201071413A1 (ru) 2011-06-30
KR20110011707A (ko) 2011-02-08
EP2306977A1 (en) 2011-04-13
CA2724194C (en) 2017-06-27
PT2772249T (pt) 2017-08-08
HUE033103T2 (en) 2017-11-28
JP2020073574A (ja) 2020-05-14
CA2965185A1 (en) 2009-12-03
AU2009252210A1 (en) 2009-12-03
SG191628A1 (en) 2013-07-31
PT2306977E (pt) 2014-09-22
ES2907982T3 (es) 2022-04-27
JP2014133765A (ja) 2014-07-24
EP2772249A1 (en) 2014-09-03
PT3714877T (pt) 2022-03-10
US20110152264A1 (en) 2011-06-23
KR101820816B1 (ko) 2018-01-22
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
JP2021120412A (ja) 2021-08-19
KR20180008905A (ko) 2018-01-24
EP3714877A1 (en) 2020-09-30
PL2306977T3 (pl) 2015-01-30
EP3205334A1 (en) 2017-08-16
AU2009252210C1 (en) 2016-04-14
JP2023085558A (ja) 2023-06-20
US10864159B2 (en) 2020-12-15
CY1115565T1 (el) 2017-01-04
HRP20140979T1 (hr) 2014-11-21
US20210059931A1 (en) 2021-03-04
AR071937A1 (es) 2010-07-28
BRPI0913109A2 (pt) 2017-06-20
HRP20170769T1 (hr) 2017-08-11
SI3714877T1 (sl) 2022-05-31
GEP20156220B (en) 2015-01-26
ES2968837T3 (es) 2024-05-14
EP2306977B1 (en) 2014-08-13
WO2009145356A1 (en) 2009-12-03
SI2772249T1 (sl) 2017-08-31
KR20190067272A (ko) 2019-06-14
BRPI0913109B8 (pt) 2021-05-25
BRPI0913109B1 (pt) 2019-10-22
EP2127638A1 (en) 2009-12-02
EP4035656B1 (en) 2023-11-22
KR20200057801A (ko) 2020-05-26
DK3714877T3 (da) 2022-02-14
MY159463A (en) 2017-01-13
AU2009252210B2 (en) 2014-10-16
CN102083413B (zh) 2013-11-06
PL2772249T3 (pl) 2017-10-31
US9999593B2 (en) 2018-06-19
EP4035656A1 (en) 2022-08-03
JP2024079852A (ja) 2024-06-11
KR101650006B1 (ko) 2016-08-22
EP3714877B1 (en) 2022-01-26
DK2306977T3 (da) 2014-09-15
JP2016065095A (ja) 2016-04-28
JP6889789B2 (ja) 2021-06-18
LT2772249T (lt) 2017-09-11
ES2808050T3 (es) 2021-02-25
JP6649992B2 (ja) 2020-02-19
KR102246598B1 (ko) 2021-04-30
TW201000104A (en) 2010-01-01
PT3205334T (pt) 2020-07-31
DK2772249T3 (en) 2017-07-17
LT3714877T (lt) 2022-04-11
JP7520285B2 (ja) 2024-07-23
ES2495316T3 (es) 2014-09-17
EA023661B1 (ru) 2016-06-30
JP6148317B2 (ja) 2017-06-14
JP2011521943A (ja) 2011-07-28
TWI432202B (zh) 2014-04-01
JP6356868B2 (ja) 2018-07-11
KR102114401B1 (ko) 2020-05-25
JP2018154656A (ja) 2018-10-04
CA2724194A1 (en) 2009-12-03
EP4289446A2 (en) 2023-12-13
EP3205334B1 (en) 2020-04-29
UA102257C2 (uk) 2013-06-25
HRP20200998T1 (hr) 2020-10-16
HUE049923T2 (hu) 2020-11-30
HUE058079T2 (hu) 2022-06-28
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
PL3205334T3 (pl) 2020-11-02
ES2627837T8 (es) 2018-02-26
JO3039B1 (ar) 2016-09-05
CY1120351T1 (el) 2019-07-10
KR20160102319A (ko) 2016-08-29
CN102083413A (zh) 2011-06-01
US20180289618A1 (en) 2018-10-11
MX2010012987A (es) 2011-02-24
ES2627837T3 (es) 2017-07-31
LT3205334T (lt) 2020-09-25

Similar Documents

Publication Publication Date Title
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
MX344046B (es) Composicion de androgeno para tratar una afeccion oftalmica.
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
ECSP13013019A (es) Derivados de nucleósidos 2'- sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales
AR086490A1 (es) Composicion oftalmica de olopatadina de alta concentracion
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
CO6561789A2 (es) Método de tratamiento
UA107562C2 (uk) Спосіб лікування псоріазу
NI201100160A (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
ECSP12012033A (es) Triple combinación para bajar la presión intraocular
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
NI201000131A (es) Tratamiento para trastornos relacionados con los ojos.
EA201270097A1 (ru) Способ улучшения биодоступности латанопроста
UY32353A (es) Compuestos de soluciones oculares tópicas para suministrar concentraciones efectivas del agente activo al segmento posterior del ojo
RU2009105291A (ru) Способ лечения прогрессирующей близорукости
RU2012126870A (ru) Способ лечения прогрессирующей близорукости, протекающей на фоне относительной офтальмогипертензии
DOP2014000103A (es) Composición con un inhibidor de la bomba de protones y un antagonista h2
UA88326U (ru) Способ лечения больных с осложненными параназальными синуситами

Legal Events

Date Code Title Description
FC Refusal